Adma Biologics (ADMA) Free Cash Flow (2011 - 2025)
Adma Biologics' (ADMA) quarterly Free Cash Flow came in at $34.6 million in Q4 2025, down 27.19% YoY from $47.5 million in Q4 2024, and up 3314.42% on a QoQ basis from -$1.1 million in Q3 2025.
Adma Biologics (ADMA) Free Cash Flow (2011 - 2025) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Free Cash Flow data on file, last reported at $34.6 million in Q4 2025.
- Quarterly Free Cash Flow fell 27.19% year-over-year to $34.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.8 million (down 74.81% YoY) and the FY2025 annual result came in at $27.8 million, down 74.81% from the prior year.
- Free Cash Flow improved to $34.6 million in Q4 2025, from -$1.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $47.5 million in Q4 2024 to a low of -$37.1 million in Q4 2021.
- A 5-year average of -$2.9 million and a median of -$9.0 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow soared 728.77% — and 2025, when it plunged 433.98%.
- Tracing ADMA's Free Cash Flow over 5 years: stood at -$37.1 million in 2021, then jumped by 70.04% to -$11.1 million in 2022, then soared by 247.38% to $16.4 million in 2023, then jumped by 189.38% to $47.5 million in 2024, then retreated by 27.19% to $34.6 million in 2025.
- The last three Free Cash Flow figures came in at $34.6 million (Q4 2025), -$1.1 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.56 Mn |
| Dec 31, 2025 | 34.56 Mn |
| Sep 30, 2025 | -1.08 Mn |
| Sep 30, 2025 | -1.08 Mn |
| Jun 30, 2025 | 18.72 Mn |
| Jun 30, 2025 | 18.72 Mn |
| Mar 31, 2025 | -24.38 Mn |
| Mar 31, 2025 | -24.38 Mn |
| Dec 31, 2024 | 47.46 Mn |
| Dec 31, 2024 | 47.46 Mn |
| Sep 30, 2024 | 23.97 Mn |
| Sep 30, 2024 | 23.97 Mn |
| Jun 30, 2024 | 43.58 Mn |
| Jun 30, 2024 | 43.58 Mn |
| Mar 31, 2024 | -4.57 Mn |
| Mar 31, 2024 | -4.57 Mn |
| Dec 31, 2023 | 16.40 Mn |
| Dec 31, 2023 | 16.40 Mn |
| Sep 30, 2023 | 11.23 Mn |
| Sep 30, 2023 | 11.23 Mn |